NUVISAN GmbH
Nuvisan is a pharmaceutical research organization dedicated to advancing health care through innovative drug discovery, preclinical, clinical, CMC, and digital solutions. They partner with clients to bring therapeutics to life, offering deep scientific insights, tailored clinical solutions, and integrated data services. Their recent strategic acquisition by ALS Limited enhances their capabilities in drug discovery and development.
Industries
Nr. of Employees
Very Large (1000+)
Products
Life science database
Centralized data repository service to store and query life-science research and development datasets.
Molecular modelling and cheminformatics platform
Computational platform for molecular modelling, cheminformatics and machine-learning driven compound evaluation.
Life science database
Centralized data repository service to store and query life-science research and development datasets.
Molecular modelling and cheminformatics platform
Computational platform for molecular modelling, cheminformatics and machine-learning driven compound evaluation.
Services
Service portfolio covering omics and biomarkers, biosciences, compound screening, pharmacology, medicinal chemistry and discovery-stage DMPK.
Development-stage DMPK and preclinical safety testing to de-risk candidates prior to clinical entry.
Early-phase clinical study design and execution, including bioanalysis and biomarker implementation.
Support for drug substance and drug product development, release and stability testing, and clinical trial supply services.
Life-science database management, digital science technologies, molecular modelling, cheminformatics and applied ML for data-driven decision support.
Cross-functional project delivery combining discovery, preclinical, CMC and clinical capabilities for specific therapeutic areas and modalities.
Service portfolio covering omics and biomarkers, biosciences, compound screening, pharmacology, medicinal chemistry and discovery-stage DMPK.
Development-stage DMPK and preclinical safety testing to de-risk candidates prior to clinical entry.
Early-phase clinical study design and execution, including bioanalysis and biomarker implementation.
Support for drug substance and drug product development, release and stability testing, and clinical trial supply services.
Life-science database management, digital science technologies, molecular modelling, cheminformatics and applied ML for data-driven decision support.
Cross-functional project delivery combining discovery, preclinical, CMC and clinical capabilities for specific therapeutic areas and modalities.
Expertise Areas
- Clinical trial management (Phase I–II)
- Biomarker and omics discovery
- DMPK and ADME studies
- Preclinical safety and toxicology
Key Technologies
- Omics (genomics, proteomics, metabolomics)
- Bioinformatics and omics data analysis
- Molecular modelling
- Cheminformatics
News & Updates
The global leader in testing, ALS Limited acquired Nuvisan on April 1, 2024, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio. This strategic acquisition offers specific opportunities for customers.
Nuvisan has become the first CRO in the EU to be Gyrolab® certified, showcasing their advanced capabilities in bioanalytical services.
Nuvisan Berlin has celebrated three years of successful collaboration with Bayer Pharmaceuticals, highlighting their ongoing partnership in drug development.
The global leader in testing, ALS Limited acquired Nuvisan on April 1, 2024, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio. This strategic acquisition offers specific opportunities for customers.
Nuvisan has become the first CRO in the EU to be Gyrolab® certified, showcasing their advanced capabilities in bioanalytical services.
Nuvisan Berlin has celebrated three years of successful collaboration with Bayer Pharmaceuticals, highlighting their ongoing partnership in drug development.